Bristol Myers Beats on Revenue as Revlimid Sales Decline Slows
Bristol Myers Squibb Co. shares fell the most in four years as sales of key drugs missed Wall Street’s expectations and the company announced job cuts as part of a $1.5 billion cost-reduction program.